USP and Public Policy
Left
Refine Your Search
The USP submits comments to the Draft Guidance for Industry; Dietary Supplements: New Dietary Ingredient Notifications and Related Issues (“Guidance”) published by the Food and Drug Administration (…
Learn More
Identifying and addressing vulnerabilities in the upstream pharmaceutical supply chain are essential to mitigating and preventing drug shortages and to ensuring patients have access to the critical…
Learn More
USP Comment Letter submitted to Centers for Medicare & Medicaid Services (CMS) in response to the proposed rule “Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment…
Learn More
USP appreciates the opportunity to comment on the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q13 harmonized guideline draft.
Learn More
USP Comment Letter: Submitted to Canadian Food Inspection Agency on Proposed SFCA Regulations (2017)
USP appreciates this opportunity to submit comments on the proposed Safe Food for Canadians Regulations (the Proposed Regulations).
Learn More
Submitted on September 18, 2017 - USP Comment Letter to FDA in conjunction with the July 18, 2017 meeting on “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and…
Learn More
USP supported S. 4090, the “Dietary Supplement Listing Act of 2022.”
Learn More
USP letter provided support to the efforts of WHO’s INN expert group to develop a consensus-based global approach to the naming of all biologicals that is consistent with existing, accepted…
Learn More
USP Statement to the WHO on the quality of hand sanitizers, or handrubs, as related to public health emergencies: preparedness and response.
Learn More
United States Pharmacopeia (USP) Statement for the Record Submitted to the Senate Finance Committee for the Hearing: “Drug Shortages: Examining Supply Challenges, Impacts, and Policy Solutions from a…
Learn More